BR112022005330A2 - Organismos semissintéticos eucarióticos - Google Patents

Organismos semissintéticos eucarióticos

Info

Publication number
BR112022005330A2
BR112022005330A2 BR112022005330A BR112022005330A BR112022005330A2 BR 112022005330 A2 BR112022005330 A2 BR 112022005330A2 BR 112022005330 A BR112022005330 A BR 112022005330A BR 112022005330 A BR112022005330 A BR 112022005330A BR 112022005330 A2 BR112022005330 A2 BR 112022005330A2
Authority
BR
Brazil
Prior art keywords
eukaryotic
organisms
semissynthetic
semi
manufacture
Prior art date
Application number
BR112022005330A
Other languages
English (en)
Inventor
E Romesberg Floyd
Xiaozhou ZHOU Anne
Sheng Kai
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR112022005330A2 publication Critical patent/BR112022005330A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

ORGANISMOS SEMISSINTÉTICOS EUCARIÓTICOS. São fornecidos aqui organismos semissintéticos eucarióticos e seus métodos de uso e fabricação.
BR112022005330A 2019-09-30 2020-09-29 Organismos semissintéticos eucarióticos BR112022005330A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908421P 2019-09-30 2019-09-30
PCT/US2020/053339 WO2021067313A1 (en) 2019-09-30 2020-09-29 Eukaryotic semi-synthetic organisms

Publications (1)

Publication Number Publication Date
BR112022005330A2 true BR112022005330A2 (pt) 2022-08-23

Family

ID=75336479

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005330A BR112022005330A2 (pt) 2019-09-30 2020-09-29 Organismos semissintéticos eucarióticos

Country Status (12)

Country Link
US (1) US20220228148A1 (pt)
EP (1) EP4041247A4 (pt)
JP (1) JP2022549931A (pt)
KR (1) KR20220075231A (pt)
CN (1) CN114746099A (pt)
AU (1) AU2020357614A1 (pt)
BR (1) BR112022005330A2 (pt)
CA (1) CA3151762A1 (pt)
IL (1) IL291635A (pt)
MX (1) MX2022003825A (pt)
TW (1) TW202128994A (pt)
WO (1) WO2021067313A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59991B1 (sr) 2013-08-08 2020-04-30 Scripps Research Inst Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
EP3475295B1 (en) 2016-06-24 2022-08-10 The Scripps Research Institute Novel nucleoside triphosphate transporter and uses thereof
EP3652316A4 (en) 2017-07-11 2021-04-07 Synthorx, Inc. INTEGRATION OF NON-NATURAL NUCLEOTIDES AND METHOD FOR THEREFORE
BR112021025130A2 (pt) 2019-06-14 2022-03-15 Scripps Research Inst Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016364229A1 (en) * 2015-11-30 2018-05-31 European Molecular Biology Laboratory Means and methods for preparing engineered proteins by genetic code expansion in insect cells
EP3652316A4 (en) * 2017-07-11 2021-04-07 Synthorx, Inc. INTEGRATION OF NON-NATURAL NUCLEOTIDES AND METHOD FOR THEREFORE
US20200224234A1 (en) * 2017-07-11 2020-07-16 The Scripps Research Institute Incorporation of unnatural nucleotides and methods of use in vivo thereof

Also Published As

Publication number Publication date
EP4041247A4 (en) 2024-03-06
US20220228148A1 (en) 2022-07-21
MX2022003825A (es) 2022-05-11
IL291635A (en) 2022-05-01
KR20220075231A (ko) 2022-06-07
CA3151762A1 (en) 2021-04-08
WO2021067313A1 (en) 2021-04-08
TW202128994A (zh) 2021-08-01
JP2022549931A (ja) 2022-11-29
AU2020357614A1 (en) 2022-03-31
CN114746099A (zh) 2022-07-12
EP4041247A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
BR112022005330A2 (pt) Organismos semissintéticos eucarióticos
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020010303A2 (es) Conjugados de il-15, y sus usos
MX2020013169A (es) Conjugados de camptotecina.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
PH12020551716A1 (en) Anti-ror antibody constructs
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
MX2021016050A (es) Formulaciones transdermicas.
CL2023000894A1 (es) Compuestos de heteroarilo fusionados y su uso como inhibidores de camkii
MX2020011470A (es) Metodos de terapia genica.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2022006750A (es) Inhibidores de masp-2 y metodos de uso.
MX2022006577A (es) Formulaciones liquidas de tasimelteon y metodos para su uso.
CO2023000505A2 (es) Anticuerpos anti-notch2 y métodos de uso
TWD202471S (zh) 天線
AU2017257061A1 (en) Lipophosphonoxins of second generation, and their use
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.